3-[(2,5-Dichlorothiophen-3-yl)methyl]-5-methyl-2-pyrazin-2-ylimidazole-4-carboxylic acid

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 唑类
• 英文名称: 3-[(2,5-Dichlorothiophen-3-yl)methyl]-5-methyl-2-pyrazin-2-ylimidazole-4-carboxylic acid
• 英文别名: 3-[(2,5-dichlorothiophen-3-yl)methyl]-5-methyl-2-pyrazin-2-ylimidazole-4-carboxylic acid
• 化学式: C₁₄H₁₀Cl₂N₄O₂S
• 分子量: 369.2
• InChiKey: VFFJZSIWAWTRLZ-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3
• 重原子数：
  23
• 可旋转键数：
  4
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.14
• 拓扑面积：
  109
• 氢给体数：
  1
• 氢受体数：
  6

文献信息

• PYRAZINE DERIVATIVE
  申请人：Teijin Pharma Limited

  公开号：EP3144306A1

  公开（公告）日：2017-03-22

  Provided is a novel pyrazine derivative represented by the following formula (I) or a pharmaceutically acceptable salt thereof, or a solvate thereof which is useful for treating or preventing diseases in which URAT1 is involved, including gout, hyperuricemia, hypertension, renal diseases such as interstitial nephritis and the like, diabetes, arteriosclerosis, Lesch-Nyhan syndrome, and the like.

  本发明提供了一种由下式（I）代表的新型吡嗪衍生物或其药学上可接受的盐或其溶液剂，该衍生物可用于治疗或预防URAT1参与的疾病，包括痛风、高尿酸血症、高血压、肾脏疾病（如间质性肾炎等）、糖尿病、动脉硬化、莱希-尼汉综合征等。
• PYRAZINE DERIVATIVES
  申请人：TEIJIN PHARMA LIMITED

  公开号：US20170152242A1

  公开（公告）日：2017-06-01

  Provided is a novel pyrazine derivative represented by the following formula (I) or a pharmaceutically acceptable salt thereof, or a solvate thereof which is useful for treating or preventing diseases in which URAT1 is involved, including gout, hyperuricemia, hypertension, renal diseases such as interstitial nephritis and the like, diabetes, arteriosclerosis, Lesch-Nyhan syndrome, and the like.
• US9856237B2
  申请人：——

  公开号：US9856237B2

  公开（公告）日：2018-01-02